The characterization of these cellular interactions may lead to novel strategies for disarming TAMs’ tumor-promoting functions by targeting either upstream regulators (e.g., IL-4) or downstream effectors (e.g., cathepsins, EGF signaling), and could have potential as monotherapies or complements to conventional anticancer therapies. This evidence concerns the gene IL4 and neoplasm.